dr. igor fisch
Post on 08-Mar-2016
235 Views
Preview:
DESCRIPTION
TRANSCRIPT
1 © Igor Fisch 2013 All Rights Reserved. © Copyright 2013 Selexis SA. All rights reserved.
Innovation through Clustering
with regard to Biotechnology
and
Life Science
Igor Fisch, PhD
Chairman and CEO, Selexis SA
2 © Igor Fisch 2013 All Rights Reserved.
Agenda
1. Innovation in Switzerland: How to stimulate innovation and bring it to the market: the example of Venture Kick initiative
2. Clustering in Biotech: Is this a necessity? One example of bio-incubators in Geneva 3. Private experience starting and running businesses
Selexis SA BioXpress Therapeutics SA Viroblock SA Stemergie Biotechnology SA Affitech A/S
4. Discussions
3 © Igor Fisch 2013 All Rights Reserved.
Innovation in Switzerland
Switzerland has a leading role in innovation and competitiveness
1. ICT 2. Electronics/Mechanics 3. Medtech 4. Lifescience (Biotech)
5. Cleantech 6. Micro-/Nanotechnology 7. Materials/Chemicals 8. Others
4 © Igor Fisch 2013 All Rights Reserved.
Venture Kick: Stimulation of Entrepreneurship
Philanthropic initiative launched by Swiss Foundations
Gebert Rüf Foundation Ernst Göhner Foundation Avina Foundation OPO Foundation Lombard Odier Foundation DebioPharm group
Pre-seed fund aiming at promoting and speeding-up new start-ups in the overall high-tech environment in Switzerland
Double the number of spin-offs In the midterm we want to double the number of spin-off projects from Swiss Universities.
Cut time-to-market by half We want to significantly speed up the process of structuring business opportunities and startup companies.
Improve the quality of spin-off projects We want to substantially improve the quality of projects in terms of Executed VC and Business Angel-Investments.
5 © Igor Fisch 2013 All Rights Reserved.
Venture Kick: How Does it Work?
A strong governance geared towards results
Management Team
Beat Schillig
Co-managing
director
Jordi Montserrat
Co-managing
director
Strategic Board
Dr. Igor Fisch
SELEXIS SA
Dr. Roger Schmid
ERNST GÖHNER
STIFTUNG
Dr. Pascale Vonmont
GEBERT RÜF
STIFTUNG
6 © Igor Fisch 2013 All Rights Reserved.
Venture Kick: The Process
7 © Igor Fisch 2013 All Rights Reserved.
Venture Kick: The Results (2007-2013)
Over 1’200 applications since September 2007
Over 600 candidates presented
302 projects received 11’020’000 CHF
Over 210 startup companies incorporated (180 still active)
57 venture kickers made it to the TOP 100 SWISS STARTUPS
Over 2’000 new jobs created (FTEs)
365’000’000 CHF in financing raised by the venture kickers
8 © Igor Fisch 2013 All Rights Reserved.
Is Clustering a Necessity?
9 © Igor Fisch 2013 All Rights Reserved.
The Clustering Effect: e.g. FONGIT Incubator
Mission Facilitate innovation and economic value creation
Incubator Founding, hosting & growing HighTech start-ups
Industries CleanTech, ICT, IT, medTech, nanotech
Collaborations CTI, and financing oganisations
Offices hosting 20+ tech companies in 3000 m2 furnished space
Services administration, accounting, financial, company foundation
Team 4 experimented coaches
Financing Fongit Seed Invest- up to 500 k CHF per company
La Fondation Genevoise pour l’Innovation Technologique (FONGIT)
10 © Igor Fisch 2013 All Rights Reserved.
The Clustering Effect: e.g. FONGIT Incubator
Incubator in Geneva grouping > 30 companies
Selexis SA (since 2001)
BioXpress Therapeutics SA (since 2010)
Viroblock SA (since 2005)
Help in Start-up phase
Help growing and managing company
Stemergie Biotechnology SA (since 2012)
Affitech A/S (2010-2012)
11 © Igor Fisch 2013 All Rights Reserved.
The Clustering Effect: my Experience 1/4
Since 2001
Biotech comp. developing production tools for the industry
Impact on COGS for manufacturing recombinant protein drugs (EPO,
Mabs)
Break-even in 2005
18 FTEs
Patent portfolio: 137 granted, 30 pending and 3 provisional
> 40 products in clinical trials, manufactured with Selexis’ technologies
12 © Igor Fisch 2013 All Rights Reserved.
The Clustering Effect: my Experience 2/4
Since 2005
Biotech company developing products to fight pathogenic viral infections
Product efficient against all types of enveloped viruses (e.g. influenza, HIV,…)
Product positioned to deliver topical anti-viral products (such as masks)
13 © Igor Fisch 2013 All Rights Reserved.
The Clustering Effect: my Experience 3/4
Philosophy: all patients should have access to safe and high-quality biologic
therapeutics at affordable costs.
Products: high-quality biosimilar biologic APIs for unmet need indications such
as cancer, inflammation and autoimmunity
Mission: Cost-competitive biosimilar biologic API (MAb and MAb-like biosimilar
drugs) to the highest EMA safety and quality standards.
Since 2005
14 © Igor Fisch 2013 All Rights Reserved.
The Clustering Effect: my Experience 4/4
15 © Igor Fisch 2013 All Rights Reserved.
Discussions
top related